Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • clinical trial

    Tag: clinical trial

    You Searched For "clinical-trial"
    Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen

    Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen

    Meghna A Singhania30 April 2019 4:46 AM GMT
    Glenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
    Pfizer gets EU nod to VIZIMPRO for treating lung cancer

    Pfizer gets EU nod to VIZIMPRO for treating lung cancer

    Farhat Nasim6 April 2019 4:10 AM GMT
    New Delhi: Pfizer Inc. recently announced that the European Commission has approved VIZIMPRO (dacomitinib), a tyrosine kinase inhibitor (TKI), as...
    Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark

    Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate

    Meghna A Singhania31 March 2019 8:09 AM GMT
    New Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard...
    Roche drug cocktail doubles chance of holding lung cancer at bay

    Roche drug cocktail doubles chance of holding lung cancer at bay

    Ruby Khatun Khatun9 Dec 2017 4:15 AM GMT
    ZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
    Trial results of Zika vaccine Sanofi dropped show promise

    Trial results of Zika vaccine Sanofi dropped show promise

    Ruby Khatun Khatun6 Dec 2017 4:15 AM GMT
    CHICAGO: A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of...
    Takeda moves ahead in Zika race with launch of vaccine trial

    Takeda moves ahead in Zika race with launch of vaccine trial

    Ruby Khatun Khatun30 Nov 2017 4:00 AM GMT
    LONDON: Japan's Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical...
    Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

    Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

    Ruby Khatun Khatun24 Nov 2017 4:00 AM GMT
    Denmark: Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its...
    Roche win boosts case for adding chemo to cancer immunotherapy

    Roche win boosts case for adding chemo to cancer immunotherapy

    Ruby Khatun Khatun23 Nov 2017 4:00 AM GMT
    LONDON: Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them...
    GSK appoints scientist Barron as new Research and Development head

    GSK appoints scientist Barron as new Research and Development head

    Ruby Khatun Khatun10 Nov 2017 4:17 AM GMT
    LONDON: GlaxoSmithKline (GSK) has poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head as new Chief...
    Roche Perjeta regimen gets FDA priority review in breast cancer

    Roche Perjeta regimen gets FDA priority review in breast cancer

    Ruby Khatun Khatun4 Oct 2017 3:50 AM GMT
    ZURICH: The U.S. Food and Drug Administration (FDA) has granted a priority review for Roche's Perjeta in combination with Herceptin and chemotherapy...
    Bristols drug cocktail cuts kidney cancer death risk 37 percent

    Bristols drug cocktail cuts kidney cancer death risk 37 percent

    Ruby Khatun Khatun14 Sep 2017 3:55 AM GMT
    MADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
    AstraZeneca rebuilds cancer drug hopes with new lung data

    AstraZeneca rebuilds cancer drug hopes with new lung data

    Ruby Khatun Khatun12 Sep 2017 4:02 AM GMT
    MADRID: Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset...
    PrevNext

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X